ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) recently released a strong earnings report, and the market responded ...

Second Quarter 2025 Results Key Financial Results Revenue: US$264.6m (up ...

Acadia Pharma (ACAD) is scheduled to announce Q2 earnings results on Wednesday, August 6th, after market close.

Morgan's Scott Power highlights nine ASX healthcare companies from the 2025 Bioshares Biotech Summit with catalysts over next ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Scott Cenci as Senior Vice President, Chief Information and Data Officer. In this role, Scott will lead Acadia’s digital ...

Detailed price information for Avadel Pharmaceuticals Plc ADR (AVDL-Q) from The Globe and Mail including charting and trades.

Detailed price information for Amn Healthcare Services Inc (AMN-N) from The Globe and Mail including charting and trades.

Explore ACADIA Pharmaceuticals' Q2 2025 earnings highlights, featuring strong revenue growth, DAYBUE expansion, NUPLAZID guidance raise, and robust ...

Despite firming US sales of its Rett syndrome treatment Daybue, Neuren Pharmaceuticals (ASX:NEU) says two-thirds of eligible ...

ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its price objective hoisted by JPMorgan Chase & Co. from $30.00 to $34.00 in a report released on Thursday morning,Benzinga reports. The ...

A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggests big pharma may finally be willing to place ...

Acadia Pharmaceuticals ACAD reported second-quarter 2025 earnings of 16 cents per share, which beat the Zacks Consensus Estimate of 14 cents. In the year-ago quarter, the company had reported earnings ...